Ads
related to: experimental prostate cancer drugs names list- Starting Treatment
Learn How to Find a Specialty
Pharmacy to Obtain Treatment.
- Clinical Study Results
View Clinical Study Results
and Study Data Information.
- Sign Up for Support
Sign Up to Receive Educational
Materials About Treatment.
- Downloadable Resources
Browse Helpful Resources
for Patients and Caregivers.
- Starting Treatment
Search results
Results from the WOW.Com Content Network
Experimental cancer treatments are normally available only to people who participate in formal research programs, which are called clinical trials. Occasionally, a seriously ill person may be able to access an experimental drug through an expanded access program. Some of the treatments have regulatory approval for treating other conditions.
Prostate cancer: Myelosuppression, diarrhoea, kidney failure, hypersensitivity, severe GI reactions (including perforation, ileus, colitis, etc.; all rare) and peripheral neuropathy Docetaxel: IV: As above. Breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell head and neck cancer and gastric cancer.
Pages in category "Experimental cancer drugs" The following 200 pages are in this category, out of approximately 262 total. This list may not reflect recent changes.
Seviteronel (developmental codes VT-464 and, formerly, INO-464) is an experimental cancer medication which is under development by Viamet Pharmaceuticals and Innocrin Pharmaceuticals for the treatment of prostate cancer and breast cancer. [1]
Experimental cancer drugs (262 P) D. Drugs with undisclosed chemical structures (42 P) E. Experimental anti-obesity drugs (5 C, 20 P) Experimental antiviral drugs (45 P)
Masofaniten, also known by its developmental code name EPI-7386, is an N-terminal domain antiandrogen, or antagonist of the N-terminal domain (NTD) of the androgen receptor (AR), which is under development for the treatment of prostate cancer.
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
This is a list of 5α-reductase inhibitors (5α-RIs), drugs which inhibit one or more isoforms of the enzyme 5α-reductase.This enzyme is responsible for the conversion of the androgen hormone testosterone into the more potent dihydrotestosterone (DHT) and is essential for the production of neurosteroids like allopregnanolone, tetrahydrodeoxycorticosterone (THDOC), and 3α-androstanediol from ...
Ads
related to: experimental prostate cancer drugs names list